Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Moves To Block Loophole Allowing Pharmas To Exceed Price Caps

This article was originally published in PharmAsia News

Executive Summary

India's regulator of drug prices now requires Indian drug makers to seek a separate price if they change the composition of existing drugs. The move by the National Pharmaceutical Pricing Authority is intended to block the practice of evading price controls by changing an approved composition of a drug already under price controls. The move is seen as preventing many drug makers manufacturing in India from changing the composition by adding something such as a fatty acid or wheat germ oil to a drug to justify an unregulated price. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel